Parameterizing the logistic model of tumor growth by DW-MRI and DCE-MRI data to predict treatment response and changes in breast cancer cellularity during neoadjuvant chemotherapy

Translational Oncology

Volumn 6, Issue 3, 2013, Pages 256-264

  Atuegwu, Nkiruka C ^a   Arlinghaus, Lori R ^a   Li, Xia ^a   Chakravarthy, A Bapsi ^a,b   Abramson, Vandana G ^a,b   Sanders, Melinda E ^a   Yankeelov, Thomas E ^a,c,d  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ESTROGEN RECEPTOR; EVEROLIMUS; IXABEPILONE; LAPATINIB; PACLITAXEL; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CELL COUNT; CELL DEATH; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION WEIGHTED IMAGING; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; HUMAN; MATHEMATICAL MODEL; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR CELL; TUMOR GROWTH;

EID: 84878717612     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.13130     Document Type: Article

References (36)

1. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, et al. (1998). Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16, 2672-2685.
2. Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M, and Zambetti M (1998). Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 16, 93-100.
3. Bearer EL, Lowengrub JS, Frieboes HB, Chuang Y-L, Jin F, Wise SM, Ferrari M, Agus DB, and Cristini V (2009). Multiparameter computational modeling of tumor invasion. Cancer Res 69, 4493-4501.
4. de Pillis LG, Radunskaya AE, and Wiseman CL (2005). A validated mathematical model of cell-mediated immune response to tumor growth. Cancer Res 65, 7950-7958.
5. Stein AM, Demuth T, Mobley D, Berens M, and Sander LM (2007). A mathematical model of glioblastoma tumor spheroid invasion in a three-dimensional in vitro experiment. Biophys J 92, 356-365.
6. Sugahara T, Korogi Y, Kochi M, Ikushima I, Shigematu Y, Hirai T, Okuda T, Liang L, Ge Y, Komohara Y, et al. (1999). Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 9, 53-60.
7. Chenevert TL, Stegman LD, Taylor JM, Robertson PL, Greenberg HS, Rehemtulla A, and Ross BD (2000). Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 92, 2029-2036.
8. Hayashida Y, Hirai T, Morishita S, Kitajima M, Murakami R, Korogi Y, Makino K, Nakamura H, Ikushima I, Yamura M, et al. (2006). Diffusion-weighted imaging of metastatic brain tumors: comparison with histologic type and tumor cellularity. AJNR Am J Neuroradiol 27, 1419-1425.
9. Anderson AW, Xie J, Pizzonia J, Bronen RA, Spencer DD, and Gore JC (2000). Effects of cell volume fraction changes on apparent diffusion in human cells. Magn Reson Imaging 18, 689-695.
10. Lyng H, Haraldseth O, and Rofstad EK (2000). Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging. Magn Reson Med 43, 828-836.
11. Ellingson BM, Malkin MG, Rand SD, Connelly JM, Quinsey C, LaViolette PS, Bedekar DP, and Schmainda KM (2010). Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging 31, 538-548.
12. Pickles MD, Gibbs P, Lowry M, and Turnbull LW (2006). Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging 24, 843-847.
13. Sharma U, Danishad KKA, Seenu V, and Jagannathan NR (2009). Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. NMR Biomed 22, 104-113.
14. Yankeelov TE, Lepage M, Chakravarthy A, Broome EE, Niermann KJ, Kelley MC, Meszoely I, Mayer IA, Herman CR, McManus K, et al. (2007). Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn Reson Imaging 25, 1-13.
15. Jensen LR, Garzon B, Heldahl MG, Bathen TF, Lundgren S, and Gribbestad IS (2011). Diffusion-weighted and dynamic contrast-enhanced MRI in evaluation of early treatment effects during neoadjuvant chemotherapy in breast cancer patients. J Magn Reson Imaging 34, 1099-1109.
16. Yankeelov TE and Gore JC (2009). Dynamic contrast enhanced magnetic resonance imaging in oncology: theory, data acquisition, analysis, and examples. Curr Med Imaging Rev 3, 91-107.
17. Johansen R, Jensen LR, Rydland J, Goa PE, Kvistad KA, Bathen TF, Axelson DE, Lundgren S, and Gribbestad IS (2009). Predicting survival and early clinical response to primary chemotherapy for patients with locally advanced breast cancer using DCE-MRI. J Magn Reson Imaging 29, 1300-1307.
18. Yu HJ, Chen J-H, Mehta RS, Nalcioglu O, and Su M-Y (2007). MRI measurements of tumor size and pharmacokinetic parameters as early predictors of response in breast cancer patients undergoing neoadjuvant anthracycline chemotherapy. J Magn Reson Imaging 26, 615-623.
19. Ah-See M-LW, Makris A, Taylor NJ, Harrison M, Richman PI, Burcombe RJ, Stirling JJ, d'Arcy JA, Collins DJ, Pittam MR, et al. (2008). Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 14, 6580-6589.
20. Hylton NM, Blume JD, Bernreuter WK, Pisano ED, Rosen MA, Morris EA, Weatherall PT, Lehman CD, Newstead GM, Polin S, et al. (2012). Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy-results from ACRIN 6657/I-SPY TRIAL. Radiology 263, 663-672.
21. Ellingson BM, LaViolette PS, Rand SD, Malkin MG, Connelly JM, Mueller WM, Prost RW, and Schmainda KM (2011). Spatially quantifying microscopic tumor invasion and proliferation using a voxel-wise solution to a glioma growth model and serial diffusion MRI. Magn Reson Med 65, 1131-1143.
22. Szeto MD, Chakraborty G, Hadley J, Rockne R, Muzi M, Alvord EC Jr, Krohn KA, Spence AM, and Swanson KR (2009). Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. Cancer Res 69, 4502-4509.
23. Konukoglu E, Clatz O, Menze BH, Stieltjes B, Weber MA, Mandonnet E, Delingette H, and Ayache N (2010). Image guided personalization of reactiondiffusion type tumor growth models using modified anisotropic eikonal equations. IEEE Trans Med Imaging 29, 77-95.
24. Atuegwu NC, Colvin DC, Loveless ME, Xu L, Gore JC, and Yankeelov TE (2012). Incorporation of diffusion-weighted magnetic resonance imaging data into a simple mathematical model of tumor growth. Phys Med Biol 57, 225-240.
25. Atuegwu NC, Arlinghaus LR, Li X, Welch EB, Chakravarthy BA, Gore JC, and Yankeelov TE (2011). Integration of diffusion-weighted MRI data and a simple mathematical model to predict breast tumor cellularity during neoadjuvant chemotherapy. Magn Reson Med 66, 1689-1696.
26. Stejskal EO and Tanner JE (1965). Spin diffusion measurements: spin echoes in the presence of a time-dependent field gradient. J Chem Phys 42, 288-292.
27. Landis CS, Li X, Telang FW, Coderre JA, Micca PL, Rooney WD, Latour LL, Vetek G, Palyka I, and Springer CS Jr (2000). Determination of the MRI contrast agent concentration time course in vivo following bolus injection: effect of equilibrium transcytolemmal water exchange. Magn Reson Med 44, 563-574.
28. Yankeelov TE, Rooney WD, Li X, and Springer CS Jr (2003). Variation of the relaxographic "shutter-speed" for transcytolemmal water exchange affects the CR bolus-tracking curve shape. Magn Reson Med 50, 1151-1169.
29. Tofts PS (1997). Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 7, 91-101.
30. Li X, Welch EB, Arlinghaus LR, Chakravarthy AB, Xu L, Farley J, Loveless ME, Mayer IA, Kelley MC, Meszoely IM, et al. (2011). A novel AIF tracking method and comparison of DCE-MRI parameters using individual and population-based AIFs in human breast cancer. Phys Med Biol 56, 5753-5769.
31. Woodhams R, Ramadan S, Stanwell P, Sakamoto S, Hata H, Ozaki M, Kan S, and Inoue Y (2011). Diffusion-weighted imaging of the breast: principles and clinical applications. Radiographics 31, 1059-1084.
32. Martin I, Dozin B, Quarto R, Cancedda R, and Beltrame F (1997). Computerbased technique for cell aggregation analysis and cell aggregation in in vitro chondrogenesis. Cytometry 28, 141-146.
33. Byrne HM (2003). Modelling avascular tumor growth. In Cancer Modelling and Simulation. L Preziosi (Ed). Chapman & Hall/CRC, Boca Raton, FL. pp. 75-120.
34. Henderson E, Rutt BK, and Lee TY (1998). Temporal sampling requirements for the tracer kinetics modeling of breast disease. Magn Reson Imaging 16, 1057-1073.
35. Wang Y, Huang W, Panicek DA, Schwartz LH, and Koutcher JA (2008). Feasibility of using limited-population-based arterial input function for pharmacokinetic modeling of osteosarcoma dynamic contrast-enhanced MRI data. Magn Reson Med 59, 1183-1189.
36. Meng R, Chang SD, Jones EC, Goldenberg SL, and Kozlowski P (2010). Comparison between population average and experimentally measured arterial input function in predicting biopsy results in prostate cancer. Acad Radiol 17, 520-525.